ストックスクリーナーアプリを入手
4.88
1.01%
-0.05
アフターアワーズ：
4.78
-0.10
-2.05%
前日終値:
$4.93
開ける：
$4.96
24時間の取引高:
61,320
Relative Volume:
0.01
時価総額：
$16.86M
収益：
-
当期純損益:
$-37.75M
株価収益率:
-1.5015
EPS:
-3.25
ネットキャッシュフロー:
$-30.91M
1週間 パフォーマンス:
+1.67%
1か月 パフォーマンス:
+1,043%
6か月 パフォーマンス:
+1,629%
1年 パフォーマンス:
+97.57%
1日の値動き範囲:
$4.80
$5.0454
1週間の範囲:
$4.62
$5.05
52週間の値動き範囲:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
名前
Cellectar Biosciences Inc
セクター
電話
(608) 441-8120
住所
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.88 | 16.86M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | 再開されました | Ladenburg Thalmann | Buy |
| 2020-07-01 | 開始されました | Oppenheimer | Outperform |
| 2020-01-21 | 再開されました | ROTH Capital | Buy |
| 2019-09-13 | 開始されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Cellectar reports improved survival in pediatric brain tumor trial - Investing.com
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus
Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan
Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences announces $2.5 million stock sale By Investing.com - Investing.com India
Cellectar Biosciences Enters into Common Stock Agreements to Rai - GuruFocus
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise - marketscreener.com
Cellectar Biosciences (CLRB) Secures $2.5 Million from Stock Sal - GuruFocus
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
Cellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar Biosciences (CLRB) Secures $2.5M Through Stock Sale Agreements | CLRB Stock News - GuruFocus
Cellectar Biosciences announces $2.5 million stock sale - Investing.com Australia
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules | CLRB Stock News - GuruFocus
Cellectar Biosciences Enters into Common Stock Agreements - GlobeNewswire
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance
FDA Designation Sparks Rally For This Biotech - The Globe and Mail
Cellectar Biosciences stock soars on FDA breakthrough designation - Investing.com Australia
Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com - Investing.com Canada
Cellectar Biosciences Stock Price, Quotes and Forecasts | NASDAQ:CLRB - Benzinga
Cellectar Biosciences (CLRB) Secures Breakthrough Therapy Designation | CLRB Stock News - GuruFocus
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained - Yahoo Finance
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings - Benzinga
Cellectar Granted U.S. FDA Breakthrough Therapy Designation - GlobeNewswire
Cellectar Biosciences Says FDA Granted Breakthrough Therapy Designation for Experimental Cancer Drug; Shares Rise Pre-Bell - marketscreener.com
Cellectar Biosciences (CLRB) Gains FDA Breakthrough Therapy Desi - GuruFocus
Cellectar Biosciences Announces Breakthrough Therapy Designation for iopofosine I 131, Reports 83.6% Overall Response Rate from CLOVER WaM Phase 2 Study - Nasdaq
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) - Quantisnow
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN
Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister
Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World
Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World
Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks
Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Inc (CLRB) 財務データ
収益
当期純利益
現金流量
EPS
Cellectar Biosciences Inc (CLRB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):